Posterior Reversible Encephalopathy Syndrome in the Critically Ill Patients

Sponsor
Ictal Group (Other)
Overall Status
Recruiting
CT.gov ID
NCT03470467
Collaborator
Versailles Hospital (Other)
300
1
129.8
2.3

Study Details

Study Description

Brief Summary

Posterior Reversible Encephalopathy Syndrome prospective (PRES) registry. Data collection using a standardized form : demographic data and data related to the PRES, including circumstances of onset, dates and times of onset and of symptoms control, on-scene clinical findings, clinical and radiological features of PRES, pre-hospital and hospital care providers, timing of antiepileptic, antihypertensive drugs and supportive treatments, results of etiological investigations, cause of PRES, type and dosage of antiepileptic and antihypertensive drugs. Dates and times of EEG monitoring, EEG results, radiological and biological investigations. Outcomes including vital status and Glasgow Outcome Scale score at ICU and hospital discharge, day-90 and 1-year after SE and determined based on data in the ICU and/or neurologist charts and/or patients phone interview

Condition or Disease Intervention/Treatment Phase
  • Other: No intervention

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
300 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Posterior Reversible Encephalopathy Syndrome in the Critically Ill Patients
Actual Study Start Date :
Mar 9, 2018
Anticipated Primary Completion Date :
Dec 31, 2028
Anticipated Study Completion Date :
Dec 31, 2028

Outcome Measures

Primary Outcome Measures

  1. Favorable outcome [1 year]

    A favorable outcome is defined by a Glasgow Outcome Scale (GOS) of 5. The Glasgow Outcome Scale (GOS) will be determined during a structured interview conducted by an independent assessor. The GOS score : [1: Death, 2: Persistent vegetative state, 3: Severe disability, 4: Moderate disability, 5 : Low disability]

Secondary Outcome Measures

  1. Favorable outcome [3-months and 5-years, 10-years]

    A favorable outcome is defined by a Glasgow Outcome Scale (GOS) of 5. The Glasgow Outcome Scale (GOS) will be determined during a structured interview conducted by an independent assessor. The GOS score : [1: Death, 2: Persistent vegetative state, 3: Severe disability, 4: Moderate disability, 5 : Low disability]

  2. Functional impairment [3-months and 1-year, 5-years, 10-years]

    Percentages of patients with functional impairments (motor, sensitive or cognitive deficits)

  3. Low or moderate disability [3-months and 1-year, 5-years, 10-years]

    Low or moderate disability is defined by a Glasgow Outcome Scale (GOS) of 4 or 5. The Glasgow Outcome Scale (GOS) will be determined during a structured interview conducted by an independent assessor. The GOS score : [1: Death, 2: Persistent vegetative state, 3: Severe disability, 4: Moderate disability, 5 : Low disability]

  4. Recurrent PRES [3-months and 1-year, 5-years, 10-years]

    percentages of the patients that experience recurrence of PRES [defined as a variable combination of consciousness impairment, seizure activity, headaches, visual abnormalities, nausea/vomiting, and focal neurological signs AND cerebral imaging abnormalities involving the white matter (brain CT scan hypodensities AND/OR Brain MRI hypoT1, hyper T2 FLAIR)]

  5. Mortality rate [ICU, hospital discharge, 3-months and 1-year, 5-years, 10-years]

    mortality rate

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • age >= 18 years

  • Posterior Reversible Encephalopathy Syndrome defined as:

  • combination of consciousness impairment, seizure activity, headaches, visual abnormalities, nausea/vomiting, and focal neurological signs AND

  • cerebral imaging abnormalities involving the white matter (brain CT scan hypodensities AND/OR Brain MRI hypoT1, hyper T2 FLAIR)

  • intensive care unit admission

Exclusion Criteria:
  • normal cerebral imaging

Contacts and Locations

Locations

Site City State Country Postal Code
1 Intensive Care Unit - Versailles Hospital Le Chesnay France 78150

Sponsors and Collaborators

  • Ictal Group
  • Versailles Hospital

Investigators

  • Principal Investigator: Stephane LEGRIEL, MD, Ictal Group

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ictal Group
ClinicalTrials.gov Identifier:
NCT03470467
Other Study ID Numbers:
  • ICTAL PRES REGISTRY
First Posted:
Mar 20, 2018
Last Update Posted:
Aug 8, 2019
Last Verified:
Jul 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 8, 2019